<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HBBAAC2088BEA4F21A64F4CBDC0C79C6B" public-private="public" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 1600 IH: Patients’ Access to Treatments Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-03-25</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code> 
<congress>114th CONGRESS</congress>
<session>1st Session</session>
<legis-num>H. R. 1600</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20150325">March 25, 2015</action-date> 
<action-desc><sponsor name-id="M001180">Mr. McKinley</sponsor> (for himself, <cosponsor name-id="C001036">Mrs. Capps</cosponsor>, <cosponsor name-id="H001055">Mr. Heck of Nevada</cosponsor>, <cosponsor name-id="J000288">Mr. Johnson of Georgia</cosponsor>, <cosponsor name-id="H001045">Mr. Harper</cosponsor>, <cosponsor name-id="S001157">Mr. David Scott of Georgia</cosponsor>, <cosponsor name-id="Y000033">Mr. Young of Alaska</cosponsor>, <cosponsor name-id="L000580">Ms. Michelle Lujan Grisham of New Mexico</cosponsor>, <cosponsor name-id="F000451">Mr. Fitzpatrick</cosponsor>, <cosponsor name-id="P000523">Mr. Price of North Carolina</cosponsor>, <cosponsor name-id="E000215">Ms. Eshoo</cosponsor>, <cosponsor name-id="C001090">Mr. Cartwright</cosponsor>, <cosponsor name-id="H001038">Mr. Higgins</cosponsor>, <cosponsor name-id="T000469">Mr. Tonko</cosponsor>, <cosponsor name-id="R000577">Mr. Ryan of Ohio</cosponsor>, <cosponsor name-id="P000597">Ms. Pingree</cosponsor>, <cosponsor name-id="T000465">Ms. Tsongas</cosponsor>, <cosponsor name-id="C001101">Ms. Clark of Massachusetts</cosponsor>, <cosponsor name-id="T000468">Ms. Titus</cosponsor>, <cosponsor name-id="S001150">Mr. Schiff</cosponsor>, <cosponsor name-id="B001285">Ms. Brownley of California</cosponsor>, <cosponsor name-id="G000571">Ms. Gabbard</cosponsor>, <cosponsor name-id="K000375">Mr. Keating</cosponsor>, <cosponsor name-id="I000057">Mr. Israel</cosponsor>, <cosponsor name-id="N000147">Ms. Norton</cosponsor>, <cosponsor name-id="C001072">Mr. Carson of Indiana</cosponsor>, <cosponsor name-id="B001251">Mr. Butterfield</cosponsor>, <cosponsor name-id="D000191">Mr. DeFazio</cosponsor>, <cosponsor name-id="T000193">Mr. Thompson of Mississippi</cosponsor>, <cosponsor name-id="B000574">Mr. Blumenauer</cosponsor>, <cosponsor name-id="G000559">Mr. Garamendi</cosponsor>, <cosponsor name-id="H000324">Mr. Hastings</cosponsor>, <cosponsor name-id="P000608">Mr. Peters</cosponsor>, <cosponsor name-id="W000799">Mr. Walz</cosponsor>, <cosponsor name-id="S000480">Ms. Slaughter</cosponsor>, <cosponsor name-id="M000312">Mr. McGovern</cosponsor>, <cosponsor name-id="N000127">Mr. Nolan</cosponsor>, <cosponsor name-id="Q000023">Mr. Quigley</cosponsor>, <cosponsor name-id="J000296">Mr. Jolly</cosponsor>, <cosponsor name-id="F000030">Mr. Farr</cosponsor>, <cosponsor name-id="D000598">Mrs. Davis of California</cosponsor>, <cosponsor name-id="S000522">Mr. Smith of New Jersey</cosponsor>, <cosponsor name-id="L000559">Mr. Langevin</cosponsor>, <cosponsor name-id="M001185">Mr. Sean Patrick Maloney of New York</cosponsor>, <cosponsor name-id="L000565">Mr. Loebsack</cosponsor>, <cosponsor name-id="P000604">Mr. Payne</cosponsor>, <cosponsor name-id="N000002">Mr. Nadler</cosponsor>, <cosponsor name-id="C001068">Mr. Cohen</cosponsor>, <cosponsor name-id="B001292">Mr. Beyer</cosponsor>, <cosponsor name-id="D000399">Mr. Doggett</cosponsor>, and <cosponsor name-id="R000053">Mr. Rangel</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes.</official-title> 
</form> 
<legis-body id="H3C1F6628A4AB47F7BB93B1454B7D1E0F" style="OLC"> 
<section id="H7FFDF7D2D4B845CBB0377FDD7D62E3FD" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Patients’ Access to Treatments Act of 2015</short-title></quote>.</text></section> <section id="HD0611C0444CB4CECBC07DDBF6830CC30"><enum>2.</enum><header>Cost-sharing requirements applicable to prescription drugs in a specialty drug tier</header> <subsection id="H6997006A43E64CE7B8922594EC1088EF"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Subpart II of part A of title XXVII of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300gg">42 U.S.C. 300gg et seq.</external-xref>) is amended by adding at the end the following:</text> 
<quoted-block display-inline="no-display-inline" id="H886796A15E2B49CC896A24A3697FA8BF" style="OLC"> 
<section id="HD20159A8625342E29486FF2F06F6BEC7"><enum>2719B.</enum><header>Cost-sharing requirements applicable to prescription drugs in a specialty drug tier</header> 
<subsection id="H478E31EA3DCB4D46A2ECC8BC8BAC503A"><enum>(a)</enum><header>Requirement</header><text>A group health plan, or a health insurance issuer offering group or individual health insurance, that provides coverage for prescription drugs and uses a formulary or other tiered cost-sharing structure shall not impose cost-sharing requirements applicable to prescription drugs in a specialty drug tier that exceed the dollar amount (or its equivalent) of cost-sharing requirements applicable to prescription drugs in a non-preferred brand drug tier (or prescription drugs in a brand drug tier if there is no non-preferred brand drug tier).</text></subsection> <subsection id="H6545FBA9EF504A849340DEC18FFBF9E8"><enum>(b)</enum><header>Special rule</header><text>If a formulary used by a group health plan or a health insurance issuer offering group or individual health insurance contains more than one non-preferred brand drug tier, then the requirements of subsection (a) shall be applied with respect to the non-preferred brand drug tier for which beneficiary cost-sharing is lowest.</text></subsection> 
<subsection id="H1F4367F0908049B8AB1A26B89967D7FA"><enum>(c)</enum><header>Definitions</header><text display-inline="yes-display-inline">In this section:</text> <paragraph id="H8681732C79624751B0BF495AAFE975C4"><enum>(1)</enum><text>The term <term>cost-sharing</term> includes co-payment and coinsurance.</text></paragraph> 
<paragraph id="H466939EE45A442C3B4C6CC8A8D2B8CCD"><enum>(2)</enum><text>The term <term>drug tier</term> means, with respect to a group health plan or health insurance issuer offering group or individual health insurance coverage that uses a formulary or other cost-sharing structure, a category of drugs—</text> <subparagraph id="H15EB1F2D0C664148938931992D0FE9EC"><enum>(A)</enum><text>within such formulary or structure for which the total dollar amount of cost-sharing requirements for any drug does not vary by more than ten percent from the total dollar amount of cost-sharing requirements for any other drug; and</text></subparagraph> 
<subparagraph id="H6458B7706E4C40BF917492EBC8E04E6C"><enum>(B)</enum><text>that are prescription drugs.</text></subparagraph></paragraph> <paragraph id="H427B49887D334DA5BBFAEEE12AC3F5AF"><enum>(3)</enum><text>The term <term>non-preferred brand drug tier</term> means, with respect to a group health plan or health insurance issuer offering group or individual health insurance coverage that uses a formulary or other tiered cost-sharing structure, a category of drugs—</text> 
<subparagraph id="H725E537436994A05AD600EBC43B1B939"><enum>(A)</enum><text display-inline="yes-display-inline">within a drug tier in such formulary or structure for which beneficiary cost-sharing is greater than drug tiers for generic drugs or preferred brand drugs in the formulary or structure;</text></subparagraph> <subparagraph id="H3313987C3D1F40849504CC11CAB0C4E0"><enum>(B)</enum><text>that are prescription drugs; and</text></subparagraph> 
<subparagraph id="H07C1910CC27347E193E19F4C2F0A7D26"><enum>(C)</enum><text>that are not included within a specialty drug tier.</text></subparagraph></paragraph> <paragraph id="H242280E3532A421EB8ECC5DE6F71ACE8"><enum>(4)</enum><text>The term <term>prescription drug</term> means—</text> 
<subparagraph id="H47FE202B60034C84BD8A88432275334A"><enum>(A)</enum><text>a drug subject to section 503(b)(1) of the Federal Food, Drug, or Cosmetic Act; and</text></subparagraph> <subparagraph id="H3D456C948D03489192A35F005DE6ACEE"><enum>(B)</enum><text>includes a drug described in subparagraph (A) that is a biological product (as defined in section 351(i) of this Act).</text></subparagraph></paragraph> 
<paragraph id="HA2A371527FA840C5AA88758B2139729B"><enum>(5)</enum><text>The term <term>specialty drug tier</term> means, with respect to a group health plan or health insurance issuer offering group or individual health insurance coverage that uses a formulary or other tiered cost-sharing structure, a category of drugs—</text> <subparagraph id="H63EDE694982549F0A7B066E0FE9D7C96"><enum>(A)</enum><text display-inline="yes-display-inline">within a drug tier in such formulary or structure for which beneficiary cost-sharing is greater than drug tiers for generic drugs, preferred brand drugs, or non-preferred drugs in the plan’s formulary; and</text></subparagraph> 
<subparagraph id="H809987ABA4F4436BBC49AC8145CEE609"><enum>(B)</enum><text>that are prescription drugs.</text></subparagraph></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection> <subsection id="H29E497BD2F6D481C94CBF20870BEDC43"><enum>(b)</enum><header>Effective date</header><text>Section 2719B of the Public Health Service Act, as added by subsection (a), applies to plan years beginning on or after the date of the enactment of this Act.</text></subsection></section> 
</legis-body> 
</bill> 

